Status:
NO_LONGER_AVAILABLE
Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to provide sildenafil therapy to patients who completed the A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio™ is not supplied by Healt...
Eligibility Criteria
Inclusion
- Subject who completed the A1481244 study and are judged by the Investigator to derive clinical benefit from continuous treatment with Sildenafil 20 mg therapy.
- Subject who resides in a Brazilian State where Sildenafil is not supplied by State Health Secretary.
Exclusion
- Pregnant or lactating women.
- Current participation in other studies and during study participation.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00866983
Last Update
February 1 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil, 90610-000
2
Pfizer Investigational Site
São Paulo, São Paulo, Brazil, 04012-909